Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Melanoma 69Leukemia, Myeloid, Acute 32Carcinoma, Renal Cell 27Neoplasm Metastasis 17Breast Neoplasms 16Leukemia 15Neuroblastoma 14Kidney Neoplasms 14Lymphoma, Non-Hodgkin 12Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Myelodysplastic Syndromes 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Congenital Abnormalities 7Colorectal Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Mesothelioma, Malignant 4Lung Neoplasms 4

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × Interleukin-2 × Clear all
NCT03546426 2024-10-01

MESOVAX

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 1 Active not recruiting
18 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡